关于我们
关于HLB
领导寄语
沿革
地位
集团
制药,生物科技
造船
生活·健康·餘暇活動
金融
事业
制药,生物科技
细胞毒性药物
靶向治疗药物
免疫疗法
特殊船舶
GRE PIPE事业
投资者关系
股价信息
公司公告
公关
IR LETTER
报刊
资料室
职业
招聘
中文
韩文
英文
home
Title + Content
主题+内容
主题
内容
探索
顺序
主题
题目
日子
18
LSKB ANNOUNCES ENROLLMENT OF THE FIRST PATIENTS IN THE US AND EUROPE FOR ITS ONGOING APATINIB PHASE 3 CLINICAL TRIAL IN ADVANCE
admin
17
LSKB ANNOUNCES ITS CLINICAL INITIATIVE TO STUDY THE SAFETY AND EFFICACY OF COMBINING APATINIB WITH IMMUNOTHERAPY
admin
16
LSKB ANNOUNCES COMPLETION OF ENROLLMENT FOR THE ANGEL STUDY OF RIVOCERANIB (APATINIB) IN GASTRIC CANCER
admin
15
LSK BIOPHARMA AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL CLINICAL COLLABORATION TO EVALUATE THE COMBINATION OF ANTI-ANGIOGENE
admin
14
LSKB ANNOUNCES MFDS APPROVAL TO INITIATE A PHASE I/IIA COMBINATION STUDY OF RIVOCERANIB AND PACLITAXEL AT ASAN MEDICAL CENTER (
admin
13
LSKB ANNOUNCES THAT ENROLLMENT HAS OPENED AT HUNTSMAN CANCER INSTITUTE FOR THE APPEASE STUDY COMBINING RIVOCERANIB AND PEMBROLI
admin
12
HLB Co., Ltd. launches multipurpose High-Speed Rescue Boat
admin
11
LSK BioPharma Announces Enrollment of First Patient in Phase 3 Apatinib Trial in Gastric Cancer
admin
10
Apatinib, designated as European orphan drug..'Speeding' licensing-out to market
admin
9
HLB submitted Korea & Japan, protocol plan for Apatinib clinical trial phase III
admin
<<
<
11
12
13
14
15